Prevalence in | RR (Confounder-Mortality) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Down-referral Group |
Treatment-initiation Site Group |
10 | 10.25 | 10.5 | 10.8 | 11 | 11.3 | 11.5 | 11.75 | 12 | 12.25 | 12.5 |
0.01 | 0.45 | 0.87 | 0.89 | 0.90 | 0.92 | 0.94 | 0.95 | 0.97 | 0.99 | 1.01 | 1.02 | 1.04 |
0.06 | 0.50 | 0.67 | 0.68 | 0.69 | 0.69 | 0.70 | 0.71 | 0.72 | 0.73 | 0.73 | 0.74 | 0.75 |
0.11 | 0.55 | 0.56 | 0.57 | 0.57 | 0.58 | 0.58 | 0.58 | 0.59 | 0.59 | 0.60 | 0.60 | 0.61 |
0.16 | 0.60 | 0.49 | 0.50 | 0.50 | 0.50 | 0.50 | 0.51 | 0.51 | 0.51 | 0.52 | 0.52 | 0.52 |
0.21 | 0.65 | 0.44 | 0.45 | 0.45 | 0.45 | 0.45 | 0.46 | 0.46 | 0.46 | 0.46 | 0.46 | 0.47 |
0.26 | 0.70 | 0.41 | 0.41 | 0.41 | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 | 0.43 |
0.31 | 0.75 | 0.38 | 0.38 | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 | 0.40 |
0.36 | 0.80 | 0.36 | 0.36 | 0.36 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 |
0.41 | 0.85 | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 |
0.46 | 0.90 | 0.33 | 0.33 | 0.33 | 0.33 | 0.33 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 | 0.34 |
0.51 | 0.95 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.33 | 0.33 |